A phase 2 open trial of pentoxifylline for the treatment of leprosy reactions.
Dawlah
Zubaer M
ZM
Cabrera
Aloys
A
Ahern
Kathleen
K
Levis
William R
WR
D000328:Adult; D000368:Aged; D004893:Erythema Nodosum / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D015439:Leprosy, Borderline / Q000188:drug therapy* / Q000276:immunology; D015440:Leprosy, Lepromatous / Q000188:drug therapy* / Q000276:immunology; D015441:Leprosy, Tuberculoid / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D014409:Tumor Necrosis Factor-alpha; D010431:Pentoxifylline